Health Care

BIO opposes cloning to create a new human being (reproductive cloning) because it is unsafe and unethical. However, it is important to distinguish between that and other appropriate and important uses of the technology such as cloning specific human cells, genes and other tissues that do not and cannot lead to a human being (therapeutic cloning).

The Brownback Bill (S. 1899) is Bad for American Science and Medical Progress

The public has a strong interest in protecting research and research participants. Federal policy must find the right balance in protecting participants while allowing critical research to continue.

By utilizing DNA, scientists are able to create a genetic finger print that is unique to each individual to help find and prosecute crime suspects and identify remains.

By utilizing DNA, scientists are able to create a genetic finger print that is unique to each individual to help find and prosecute crime suspects and identify remains.

Every 70 seconds someone develops Alzheimer's. By 2029 there will be 70 million retired baby boomers. If we dont find a way to treat the disease we are going to have a public health disaster.

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

Ohio is a national leader in terms of both bioscience employment and establishments. In fact the industry accounts for about 15 percent of the state’s total economic output.

Biotechnology might seem like a new science to many, but it has its roots in the work of some early big thinkers — among them George Washington Carver, arguably one of the world’s first industrial biotechnologists and the father of sustainable farming.

Scientific discoveries happen when researchers collaborate. That’s the thinking behind a partnership formed by GlaxoSmithKline and Alnylam Pharmaceuticals to share intellectual property (IP) and industrial know-how to develop new therapies to treat the world’s most neglected tropical diseases.

On Sunday, Feb. 28, millions of people around the world will observe “World Rare Disease Day”. This is an annual event sponsored in the U.S. by the National Organization for Rare Disorders (NORD) and in Europe by the European Rare Disease Organisation (EURORDIS).

Human organ transplantation is a relatively new field of medicine that is now facing a significant challenge.

October 27 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Informed Consent Information Sheet: Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors.” BIO shares FDA’s commitment to enhancing communication with, and thereby the protection of, human research subjects.
October 14 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Draft Guidance for Industry on Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products—Considerations, Content, and Format.  BIO welcomes this Draft Guidance to ensure appropriate consistency in the format and content of product labeling for all prescription drug products approved by the Agency.  
September 2 2014
 The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Current Good Manufacturing Practices—Interim Guidance for Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug and Cosmetic Act.”
August 26 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Draft Guidance for Industry on Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products – Recommended Practices (Draft Guidance).
July 31 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “The Food and Drug Administration Fiscal Year 2014-2018 Strategic Priorities.”
October 1 2014
Relationships between life sciences industry and physicians lead to stronger R&D collaboration and educate health care providers
September 22 2014
Washington, D.C. (September 22, 2014) – BIO President and CEO James Greenwood joined AdvaMed President and CEO Stephen Ubl and PhRMA President and CEO John Castellani in a letter to CMS Administrator Marilyn Tavenner highlighting ongoing concerns about a potential lack of necessary context around the Sunshine data release.  
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.